TP-0903 is being developed as a novel therapeutic for the potential treatment of a variety of cancer indications including solid tumors. TP-0903 is in capsule form and will be taken by mouth daily for 21 days followed by 7 days off.
The primary purpose of this study is to evaluate the safety of TP-0903 at different doses to find out what effects, if any, it has on people. This study will also gain information about the pharmacokinetics or PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body) and pharmacodynamic (PD) biomarkers (which are used to examine the drug effect at a tumor site
OPEN TO ACCRUAL